These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21113977)

  • 21. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
    Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
    J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
    Grigoleit GU; Kapp M; Tan SM; Unzicker C; Einsele H; Mielke S; Topp MS; Stuhler G
    Leuk Lymphoma; 2009 Dec; 50(12):2071-4. PubMed ID: 19886845
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
    Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
    Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
    Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E
    Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study.
    Kazama H; Nishina S; Seto T
    Jpn J Clin Oncol; 2024 Jul; 54(7):778-786. PubMed ID: 38643356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Gidwani P; Ramesh KH; Liu Y; Kolb EA
    Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
    Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
    Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia].
    Arakawa Y; Koh K; Aoki T; Kubota Y; Oyama R; Mori M; Hayashi M; Hanada R
    Rinsho Ketsueki; 2014 Nov; 55(11):2316-9. PubMed ID: 25501414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
    Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
    Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia.
    Zhang B; Bolognia J; Marks P; Podoltsev N
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):303-7. PubMed ID: 24908437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Last exit clofarabine?
    Faderl S
    Leuk Lymphoma; 2009 Dec; 50(12):1907-8. PubMed ID: 20001243
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
    Abbi KK; Rybka W; Ehmann WC; Claxton DF
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.